(Q36623007)

15 August 2017

0 references

1 reference

title

Valsartan/hydrochlorothiazide: a review of its use in the management of hypertension (English)

1 reference

15 August 2017

1

Antona J Wagstaff

1 reference

15 August 2017

publication date

1 January 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

66

1 reference

15 August 2017

issue

14

1 reference

15 August 2017

page(s)

1881-1901

1 reference

Global burden of hypertension: analysis of worldwide data

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666140-00011

Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666140-00011

Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666140-00011

Comparison of effects of exercise and diuretic on left ventricular geometry, mass, and insulin resistance in older hypertensive adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666140-00011

Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200666140-00011

Valsartan/hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy.

21 January 2018

1 reference

12 December 2020

Prolonged treatment with the AT1 receptor blocker, valsartan, increases small and large artery compliance in uncomplicated essential hypertension

1 reference

12 December 2020

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

1 reference

12 December 2020

Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension

1 reference

12 December 2020

A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives

1 reference

12 December 2020

Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension

1 reference

12 December 2020

Effects of valsartan/hydrochlorothiazide and amlodipine on ambulatory blood pressure and plasma norepinephrine levels in high-risk hypertensive patients

1 reference

12 December 2020

Pharmacokinetics of valsartan in patients with liver disease

1 reference

12 December 2020

Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect

1 reference

12 December 2020

VALUE: analysis of results

1 reference

12 December 2020

Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects

1 reference

12 December 2020

Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women

1 reference

12 December 2020

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

12 December 2020

Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension

1 reference

12 December 2020

Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide

1 reference

12 December 2020

Efficacy and tolerability of valsartan in combination with hydrochlorothiazide in essential hypertension

1 reference

12 December 2020

Different drug classes have variable effects on blood pressure depending on the time of day.

1 reference

12 December 2020

Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability

1 reference

12 December 2020

Ambulatory blood-pressure monitoring

1 reference

12 December 2020

Valsartan/hydrochlorothiazide

1 reference

12 December 2020

Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial

1 reference

12 December 2020

24-hour ambulatory blood-pressure effects of valsartan and hydrochlorothiazide combinations compared with amlodipine in hypertensive patients at increased cardiovascular risk: a VAST sub-study

1 reference

12 December 2020

Hypertension treatment and control in five European countries, Canada, and the United States

1 reference

12 December 2020

Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy

1 reference

12 December 2020

Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Doxazosin Atherosclerosis Progression Study in Hypertensives in the Netherlands.

1 reference

12 December 2020

Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study

1 reference

12 December 2020

Practice Guidelines For Primary Care Physicians

1 reference

12 December 2020

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

1 reference

12 December 2020

Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension

1 reference

12 December 2020

Effect of AT1 receptor blockade on endothelial function in essential hypertension

1 reference

12 December 2020

Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide

1 reference

12 December 2020

Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).

1 reference

12 December 2020

Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients

1 reference

12 December 2020

Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men.

1 reference

12 December 2020

The effect of age on the pharmacokinetics of valsartan

1 reference

12 December 2020

Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination

1 reference

12 December 2020

A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study

1 reference

12 December 2020

Antihypertensive mechanism of diuretics based on pressure-natriuresis relationship

1 reference

12 December 2020

Comparison of the effects on 24-h ambulatory blood pressure of valsartan and amlodipine, alone or in combination with a low-dose diuretic, in elderly patients with isolated systolic hypertension (Val-syst Study).

1 reference

12 December 2020

British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary

1 reference

12 December 2020

Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension

1 reference

12 December 2020

Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors

1 reference

12 December 2020

Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study

1 reference

12 December 2020

Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks

1 reference

12 December 2020

Effect of an angiotensin II type 1 receptor blocker, valsartan, on neurohumoral factors in patients with hypertension: comparison with a long-acting calcium channel antagonist, amlodipine

1 reference

12 December 2020

Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients

1 reference

12 December 2020

Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-gro

1 reference

12 December 2020

A multicenter, randomized double-blind study of valsartan/hydrochlorothiazide combination versus amlodipine in patients with mild to moderate hypertension.

1 reference

12 December 2020

Efficacy and tolerability of the combination valsartan/hydrochlorothiazide compared with amlodipine in a mild-to-moderately hypertensive Brazilian population.

1 reference

12 December 2020

Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects

1 reference

12 December 2020

Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose

1 reference

12 December 2020

Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial

1 reference

12 December 2020

Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hypercholesterolemic and hypertensive patients

1 reference

12 December 2020

Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy

1 reference

12 December 2020

Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man

1 reference

12 December 2020

Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis

1 reference

12 December 2020

Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study

1 reference

12 December 2020

Expanding the definition and classification of hypertension

1 reference

12 December 2020

Pulse Pressure Responses in Patients Treated with Valsartan and Hydrochlorothiazide Combination Therapy

1 reference

12 December 2020

Antihypertensive effects of valsartan/hydrochlorothiazide combination in essential hypertension

1 reference

12 December 2020

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

12 December 2020

Pharmacokinetics of hydrochlorothiazide in man

1 reference

12 December 2020

A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations

1 reference

12 December 2020

Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide

1 reference

12 December 2020

Lowering of blood pressure, blood pressure amplitude and heart rate by treatment with valsartan or valsartan/hydrochlorothiazide. Results of an open observation study of 11,447 hypertensives

1 reference

12 December 2020

Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men.

1 reference

12 December 2020

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

1 reference

12 December 2020

2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension

1 reference

12 December 2020

10.2165/00003495-200666140-00011

Identifiers

DOI

1 reference

Dimensions Publication ID

15 August 2017

1017194014

0 references

1 reference